Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
05/2003
05/02/2003EP1096933B1 Use of an inhibitor of cytochrome p450 optionally combined with an antifungal agent for treating mycoses
05/02/2003EP1093361B1 Plaster which contains steroids, and a method for the production and use thereof
05/02/2003EP1086103B1 Pyrido 2,3-b]indolizine derivatives and aza analogues thereof; crf 1 specific ligands
05/02/2003EP1070058B1 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
05/02/2003EP1045846B1 Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
05/02/2003EP1037886B1 Triazine angiogenesis inhibitors
05/02/2003EP1032579B1 Carbohydrate derivatives
05/02/2003EP1028748B1 Compositions providing for increased igf-i solubility
05/02/2003EP1021448B1 TRICYCLIC COMPOUNDS HAVING ACTIVITY AS Ras-FPT INHIBITORS
05/02/2003EP1019042B1 Anti-first-pass effect compounds
05/02/2003EP1015423B1 1,3-dihydroxy-20,20-dialkyl-vitamin d 3? analogs
05/02/2003EP0998272B1 Pharmaceutical composition for combination of piperidinoalkanol-decongestant
05/02/2003EP0993455B1 POLYMORPHS OF 8-CHLORO-6, 11-DIHYDRO-11- (4-PIPERIDYLIDENE) -5H-BENZO[5,6] CYCLOHEPTA[1,2-b]PYRIDINE
05/02/2003EP0988035B1 Caspases and apoptosis
05/02/2003EP0986396A4 Prion protein modulator factor (ppmf) and prion resistant animals
05/02/2003EP0979081A4 Composition and methods using an eutomer
05/02/2003EP0969834B1 Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
05/02/2003EP0963371B1 Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
05/02/2003EP0918761B1 Certain amido- and amino-substituted benzylamine derivatives; a new class of neuropeptite y1 specific ligands
05/02/2003EP0910563B1 Integrin receptor antagonists
05/02/2003EP0831837B1 Use of squalamine for the manufacture of a medicament for inhibiting nhe
05/02/2003EP0831799B1 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders
05/02/2003EP0786988B1 Use of nk1 receptor antagonists for preparing cardio-regulatory drugs
05/02/2003EP0772592B1 1H-INDOLE-1-FUNCTIONAL sPLA 2 INHIBITORS
05/02/2003EP0738150B1 Bicyclic fibrinogen antagonists
05/02/2003EP0724387B1 Angiotension ii receptor antagonists for the treatment of chronic anti-inflammatory diseases
05/02/2003EP0592521B1 Marrow-derived human mesenchymal stem cells and monoclonal antibodies specific for said cells
05/02/2003CA2411015A1 5-(alkylidene-cycloalkyl)- and 5-(alkylidene-heterocyclyl)-pyrazoles
05/02/2003CA2410466A1 Hydrazinyl and nitrogen oxide pyrazoles
05/02/2003CA2410364A1 5-heterocyclo-pyrazoles
05/01/2003WO2003035884A2 Transient immortalization
05/01/2003WO2003035883A2 Methods and compositions for inducing tumor-specific cytotoxicity
05/01/2003WO2003035879A2 Promoters to control cell differentiation
05/01/2003WO2003035873A1 Novel glutamic acid receptor and utilization thereof
05/01/2003WO2003035682A2 Peptides and protins binding to glu-pro motidfs, therapeutical compositions containing them and their applications
05/01/2003WO2003035679A2 Molecules
05/01/2003WO2003035670A2 Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis
05/01/2003WO2003035665A1 Modified l-nucleic acid
05/01/2003WO2003035663A1 Novel hydroxyalkyl indolocarbazole derivatives, preparation method and pharmaceutical compositions containing same
05/01/2003WO2003035661A1 Derivatives of etoposide and analogs, and pharmaceutical compositions containing them
05/01/2003WO2003035659A1 Acarbose purification process
05/01/2003WO2003035654A1 Phosphonic acid compounds as inhibitors of serine proteases
05/01/2003WO2003035653A1 Pyridothienopyrimidine compound and salt thereof
05/01/2003WO2003035650A1 Entry inhibitor
05/01/2003WO2003035649A1 Imidazopyridine compounds as 5-ht4 receptor modulators
05/01/2003WO2003035647A1 Alkyl ether derivatives or salts thereof
05/01/2003WO2003035646A2 Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-ht2b receptor antagonist
05/01/2003WO2003035645A1 Novel 4-(2-furoyl)aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same
05/01/2003WO2003035644A1 Benzimidazole derivatives and their use as kdr protein kinase inhibitors
05/01/2003WO2003035641A1 Novel carbamoylpyrrolidone derivative
05/01/2003WO2003035640A1 Pyrimidone compounds and pharmaceutical compositions containing the same
05/01/2003WO2003035639A1 Pyrimidine compound and medicinal composition thereof
05/01/2003WO2003035638A1 4-imidazolin-2-one compounds
05/01/2003WO2003035635A1 6-hydroxy isoflavones, derivatives and medicaments involving same
05/01/2003WO2003035627A1 Piperazine derivatives with ccr1 receptor antagonist activity
05/01/2003WO2003035626A2 Azole derivatives and pharmaceutical compositions containing them
05/01/2003WO2003035624A1 Quinoline compound
05/01/2003WO2003035622A1 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
05/01/2003WO2003035621A1 Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
05/01/2003WO2003035620A1 Bicyclic compound
05/01/2003WO2003035610A1 Sulfonamide derivative having mmp inhibitory activity
05/01/2003WO2003035603A1 Acetic acid derivatives
05/01/2003WO2003035599A1 Quarternary ammonium compounds and their use as antimuscarinic agents
05/01/2003WO2003035126A1 Process for producing biological material, drug, food, medical instrument, cell culture instrument and tissue-inducible material
05/01/2003WO2003035110A1 Treating vascular disease by inhibiting toll-like receptor-4
05/01/2003WO2003035107A1 Enzyme inhibitors for inactivating allergens
05/01/2003WO2003035099A1 Biphasic mixtures of glp-1 and insulin
05/01/2003WO2003035084A1 Superfine aqueous dispersion of noble metal for head massage
05/01/2003WO2003035081A1 Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
05/01/2003WO2003035079A1 A combination product comprising melagatran and dexamethasone
05/01/2003WO2003035077A1 N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
05/01/2003WO2003035076A1 Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
05/01/2003WO2003035075A1 Inhibitors of human phosphatidyl-inositol 3-kinase delta
05/01/2003WO2003035074A1 Drugs comprising combination of triazaspiro[5,5]undecane derivative with cytochrome p450 isozyme 3a4 inhibitor and/or p-glycoprotein inhibitor
05/01/2003WO2003035072A1 Use of flibanserin in the treatment of sexual disorders
05/01/2003WO2003035069A1 Apomorphine-containing dosage form for ameliorating male erectile dysfunction
05/01/2003WO2003035067A1 Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents
05/01/2003WO2003035066A1 2-aminoquinolone derivatives for use as impdh inhibitors
05/01/2003WO2003035065A1 Benzimidazoles and analogues and their use as protein kinases inhibitors
05/01/2003WO2003035064A1 Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors
05/01/2003WO2003035061A1 Use of indole and indoline derivatives in the treatment of obesity or for the reduction of food intake
05/01/2003WO2003035060A1 Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
05/01/2003WO2003035057A1 Inhibitors of dipeptidyl peptidase iv
05/01/2003WO2003035056A1 Combination of liponic acid and glutamine in food and pharmaceutical products
05/01/2003WO2003035055A1 Mch antagonists for the treatment of obesity
05/01/2003WO2003035052A1 Preventives/remedies for viral infection
05/01/2003WO2003035049A2 Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections
05/01/2003WO2003035047A2 Combinations comprising a selective cyclooxygenase-2 inhibitor
05/01/2003WO2003035043A2 Pharmaceutical formulation comprising more than 15% tamoxifen
05/01/2003WO2003035042A1 Use of a multi-layer controlled-release tablet comprising ropinirole for the manufacture of medicament for the treatment of fibromyalgia
05/01/2003WO2003035036A1 Montelukast granule formulation
05/01/2003WO2003035012A2 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
05/01/2003WO2003035010A2 Thymosin augmentation of genetic immunization
05/01/2003WO2003035009A2 Treatment of acute myeloid leukemia with indolinone compounds
05/01/2003WO2003035008A2 Functionalized stilbene derivatives as improved vascular targeting agents
05/01/2003WO2003035007A2 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
05/01/2003WO2003035005A2 Heteroindanes: a new class of potent cannabimimetic ligands
05/01/2003WO2003035004A2 Immunotherapy for reversing immune suppression
05/01/2003WO2003034996A2 Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
05/01/2003WO2003034995A2 Integrin targeting compounds
1 ... 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 ... 1564